Publications by authors named "Mark G Erlander"

Claim this Profile
P
Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling.
Jesse C Patterson, Andreas Varkaris, Peter J P Croucher, Maya Ridinger, Susan Dalrymple, Mark G Erlander

Cancer Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α-blockers.
Xiaolong Wang, Bingsheng Li, Anna Ciotkowska, Beata Rutz, Mark G Erlander

Eur J Pharmacol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.
Piiha-Lotta Jerevall, Jane Brock, Juan Palazzo, Tad Wieczorek, Michael Misialek, Mark G Erlander

Breast Cancer Res Treat· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Risk Human Papillomavirus Detection in Urine Samples From a Referral Population With Cervical Biopsy-Proven High-Grade Lesions.
Adriana T Lorenzi, José Humberto T Fregnani, Janel Dockter, Kerry Fitzgerald, Elizabeth Strohecker, Mark G Erlander

J Low Genit Tract Dis· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultrasensitive plasma ctDNA assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.
Inna Chen, Victoria M Raymond, Jennifer A Geis, Eric A Collisson, Benny V Jensen, Mark G Erlander

Oncotarget· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urine test for analysis in patients with non-small cell lung cancer.
Aleksandra Franovic, Victoria M Raymond, Mark G Erlander, Karen L Reckamp

J Thorac Dis· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.
Hatim Husain, Vladislava O Melnikova, Karena Kosco, Brian Woodward, Soham More, Mark G Erlander

Clin Cancer Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.
Takeo Fujii, Afsaneh Barzi, Andrea Sartore-Bianchi, Andrea Cassingena, Giulia Siravegna, Mark G Erlander

Clin Cancer Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population.
Jack Cuzick, Louise Cadman, Amar S Ahmad, Linda Ho, George Terry, Mark G Erlander

Cancer Epidemiol Biomarkers Prev· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series.
Nishan Tchekmedyian, Raja Mudad, Fernando F Blanco, Victoria M Raymond, Jordan Garst, Mark G Erlander

Lung Cancer· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.
Karen L Reckamp, Vladislava O Melnikova, Chris Karlovich, Lecia V Sequist, D Ross Camidge, Mark G Erlander

J Thorac Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer.
David Berz, Victoria M Raymond, Jordan H Garst, Mark G Erlander

Exp Hematol Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
Samuel J Klempner, Bruce Gershenhorn, Phu Tran, Thomas K Lee, Mark G Erlander

Cancer Discov· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
Judith-Anne W Chapman, Dennis C Sgroi, Paul E Goss, Elizabeth Zarella, Shemeica Binns, Mark G Erlander

Breast Cancer Res Treat· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
Dennis C Sgroi, Judy-Anne W Chapman, T Badovinac-Crnjevic, Elizabeth Zarella, Shemeica Binns, Mark G Erlander

Breast Cancer Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.
David M Hyman, Eli L Diamond, Cecile Rose T Vibat, Latifa Hassaine, Jason C Poole, Mark G Erlander

Cancer Discov· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost effectiveness of a 92-gene assay for the diagnosis of metastatic cancer.
Tanya G K Bentley, Brock E Schroeder, Catherine A Schnabel, Mark G Erlander, Wendy C Hsiao

J Med Econ· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health economic analysis of Breast Cancer Index in patients with ER+, LN- breast cancer.
Gary Gustavsen, Brock Schroeder, Patrick Kennedy, Kristin Ciriello Pothier, Mark G Erlander

Am J Manag Care· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease.
Filip Janku, Cecile Rose T Vibat, Karena Kosco, Veronica R Holley, Goran Cabrilo, Mark G Erlander

Oncotarget· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors.
Sarah E Kerr, Catherine A Schnabel, Peggy S Sullivan, Yi Zhang, Vivian J Huang, Mark G Erlander

Mod Pathol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Dennis C Sgroi, Ivana Sestak, Jack Cuzick, Yi Zhang, Catherine A Schnabel, Mark G Erlander

Lancet Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.
Yi Zhang, Catherine A Schnabel, Brock E Schroeder, Piiha-Lotta Jerevall, Rachel C Jankowitz, Mark G Erlander

Clin Cancer Res· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
Dennis C Sgroi, Erin Carney, Elizabeth Zarrella, Lauren Steffel, Shemeica N Binns, Mark G Erlander

J Natl Cancer Inst· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a 32-gene prognostic index for prostate cancer progression.
Chin-Lee Wu, Brock E Schroeder, Xiao-Jun Ma, Christopher J Cutie, Shulin Wu, Mark G Erlander

Proc Natl Acad Sci U S A· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.
Laurel A Habel, Lori C Sakoda, Ninah Achacoso, Xiao-Jun Ma, Mark G Erlander

Breast Cancer Res· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis